About Sermorelin Buy

What this site is

Sermorelin Buy is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site exists because the public record on sermorelin is unusually lopsided: a small set of solid clinical findings sits beside a large volume of adult marketing that runs well ahead of the evidence. We read the studies, report what they measured, name related-analog data as related-analog data, and leave the gaps visible rather than filling them with claims.

About the name

The word "buy" in this domain is editorial framing, not a service. Sermorelin is a formerly FDA-approved peptide that is now prepared by compounding pharmacies, and "buy" marks the availability-and-compounding conversation that surrounds it — the questions people bring when they encounter the compound. It is not a checkout, a storefront, or an offer to sell. Nothing here is dispensed, priced, or for sale; the board is a curated reading list of the literature, assembled like a night research file.

We take care to keep that distinction sharp. The negative-terms our editorial scope excludes — sourcing, vendors, ordering, pricing — are deliberately outside what this digest does.

How we handle the evidence

Three editorial rules govern the board. First, every quantitative claim is tied to a named study in the full reference list, with a DOI or PubMed ID. Second, we keep sermorelin's own GHRH-analog findings separate from the data of its neighbors — tesamorelin's body-composition numbers and ipamorelin's GHRP-class effects are labeled as theirs, never folded into sermorelin's record. Third, where the literature is thin — adult anti-aging efficacy, long-term safety, a defined adult course — we say so plainly. The honest gaps are pinned in the open, in their own clippings, because a research digest that hides its limits is not a research digest.

On the regulatory record

We try to state sermorelin's status precisely, because it is one of the most frequently garbled facts about the compound. Sermorelin was a genuine FDA-approved prescription product for growth-hormone deficiency in children; it was withdrawn from the US market in 2008 for commercial reasons — not for any safety or efficacy failure — and it is now prepared by compounding pharmacies. That is a specific history, and it is neither "never approved" nor "currently approved."

We report that record as it stands in the published and regulatory literature, and we do not editorialize about access, sourcing, or policy beyond what those sources say. The aim is a reader who leaves with the history straight and the citations in hand.